Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Olema Pharmaceuticals, Inc.OLMA · Entity 613 | CHIEF MEDICAL OFFICER | February 02, 2026 | February 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Olema Pharmaceuticals, Inc.
Report date February 02, 2026 · Filed February 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $25.65 · Expires 2036-02-01 | Direct | 250,000 |
Reported balance
After 2026-02-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-02-02 · Grant · Acquired 250,000 · Balance 250,000 F1: 25% of the shares subject to the option vest on February 2, 2027, and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date. |
| Performance Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $25.65 · Expires 2036-02-01 | Direct | 106,250 |
Reported balance
After 2026-02-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-02-02 · Grant · Acquired 106,250 · Balance 106,250 F2: The performance-based stock options will be eligible to vest during two distinct performance periods, each beginning on February 2, 2026 and ending on December 31, 2029 and December 31, 2030, respectively, based on the Issuer's stock price trading at certain pre-determined price thresholds as measured by the average closing price per share of the Issuer's stock over a consecutive thirty (30) day trading period during each such performance period. Once a price threshold is achieved, the portion of the award related to such threshold will vest upon the date set forth in the certification by the Compensation Committee certifying that such price threshold was achieved, subject to the Reporting Person's continuous service as of the applicable certification date. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the shares subject to the option vest on February 2, 2027, and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.
F2: The performance-based stock options will be eligible to vest during two distinct performance periods, each beginning on February 2, 2026 and ending on December 31, 2029 and December 31, 2030, respectively, based on the Issuer's stock price trading at certain pre-determined price thresholds as measured by the average closing price per share of the Issuer's stock over a consecutive thirty (30) day trading period during each such performance period. Once a price threshold is achieved, the portion of the award related to such threshold will vest upon the date set forth in the certification by the Compensation Committee certifying that such price threshold was achieved, subject to the Reporting Person's continuous service as of the applicable certification date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 02, 2026 Filed Feb 5, 2026 02:30 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | GrantPerformance Stock Options (Right to Buy) · Derivative | 106,250 | $0.00 Strike: $25.65 | $0.00 |
DisclosureSEC source: 0001905871-26-000002 · form4-02042026_090207.xml · derivative · entry 2 Zojwalla Naseem · CIK 0001905871 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 106,250 Underlying: Common Stock · 106,250 shares Expires 2036-02-01 F2 · derivative.exercise_date: The performance-based stock options will be eligible to vest during two distinct performance periods, each beginning on February 2, 2026 and ending on December 31, 2029 and December 31, 2030, respectively, based on the Issuer's stock price trading at certain pre-determined price thresholds as measured by the average closing price per share of the Issuer's stock over a consecutive thirty (30) day trading period during each such performance period. Once a price threshold is achieved, the portion of the award related to such threshold will vest upon the date set forth in the certification by the Compensation Committee certifying that such price threshold was achieved, subject to the Reporting Person's continuous service as of the applicable certification date. Read SEC document |
| February 02, 2026 Filed Feb 5, 2026 02:30 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | GrantStock Option (Right to Buy) · Derivative | 250,000 | $0.00 Strike: $25.65 | $0.00 |
DisclosureSEC source: 0001905871-26-000002 · form4-02042026_090207.xml · derivative · entry 1 Zojwalla Naseem · CIK 0001905871 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2036-02-01 F1 · derivative.exercise_date: 25% of the shares subject to the option vest on February 2, 2027, and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document |
| December 23, 2025 Filed Dec 24, 2025 02:40 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | Exercise / conversionStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $7.02 | $0.00 |
DisclosureSEC source: 0001905871-25-000004 · form4-12242025_021251.xml · derivative · entry 12 Zojwalla Naseem · CIK 0001905871 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 156,818 Underlying: Common Stock · 50,000 shares Expires 2032-01-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: 25% of the shares subject to the option vested on January 31, 2023 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document |
| December 23, 2025 Filed Dec 24, 2025 02:40 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | SaleCommon Stock | 99,509 | $27.66 | $2,752,418.94 |
DisclosureSEC source: 0001905871-25-000004 · form4-12242025_021251.xml · nonDerivative · entry 8 Zojwalla Naseem · CIK 0001905871 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,488 F5 · price: The weighted average sale price for the transaction reported was $27.66, and the range of prices was between $27.50 and $27.83. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| December 23, 2025 Filed Dec 24, 2025 02:40 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | Exercise / conversionCommon Stock | 50,000 | $7.02 | $351,000.00 |
DisclosureSEC source: 0001905871-25-000004 · form4-12242025_021251.xml · nonDerivative · entry 7 Zojwalla Naseem · CIK 0001905871 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 103,997 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 22, 2025 Filed Dec 24, 2025 02:40 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,182 | $0.00 Strike: $7.02 | $0.00 |
DisclosureSEC source: 0001905871-25-000004 · form4-12242025_021251.xml · derivative · entry 11 Zojwalla Naseem · CIK 0001905871 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 206,818 Underlying: Common Stock · 7,182 shares Expires 2032-01-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: 25% of the shares subject to the option vested on January 31, 2023 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document |
| December 22, 2025 Filed Dec 24, 2025 02:40 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | Exercise / conversionStock Option (Right to Buy) · Derivative | 42,818 | $0.00 Strike: $15.25 | $0.00 |
DisclosureSEC source: 0001905871-25-000004 · form4-12242025_021251.xml · derivative · entry 10 Zojwalla Naseem · CIK 0001905871 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 112,182 Underlying: Common Stock · 42,818 shares Expires 2034-01-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: 25% of the shares subject to the option vest on February 1, 2025 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document |
| December 22, 2025 Filed Dec 24, 2025 02:40 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | SaleCommon Stock | 100,000 | $28.04 | $2,804,000.00 |
DisclosureSEC source: 0001905871-25-000004 · form4-12242025_021251.xml · nonDerivative · entry 6 Zojwalla Naseem · CIK 0001905871 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,997 F4 · price: The weighted average sale price for the transaction reported was $28.04, and the range of prices was between $27.655 and $28.36. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| December 22, 2025 Filed Dec 24, 2025 02:40 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | Exercise / conversionCommon Stock | 7,182 | $7.02 | $50,417.64 |
DisclosureSEC source: 0001905871-25-000004 · form4-12242025_021251.xml · nonDerivative · entry 5 Zojwalla Naseem · CIK 0001905871 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 153,997 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 22, 2025 Filed Dec 24, 2025 02:40 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | Exercise / conversionCommon Stock | 42,818 | $15.25 | $652,974.50 |
DisclosureSEC source: 0001905871-25-000004 · form4-12242025_021251.xml · nonDerivative · entry 4 Zojwalla Naseem · CIK 0001905871 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 146,815 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 19, 2025 Filed Dec 24, 2025 02:40 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | Exercise / conversionStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $15.25 | $0.00 |
DisclosureSEC source: 0001905871-25-000004 · form4-12242025_021251.xml · derivative · entry 9 Zojwalla Naseem · CIK 0001905871 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 155,000 Underlying: Common Stock · 40,000 shares Expires 2034-01-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: 25% of the shares subject to the option vest on February 1, 2025 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document |
| December 19, 2025 Filed Dec 24, 2025 02:40 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | SaleCommon Stock | 12,921 | $28.93 | $373,804.53 |
DisclosureSEC source: 0001905871-25-000004 · form4-12242025_021251.xml · nonDerivative · entry 3 Zojwalla Naseem · CIK 0001905871 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 103,997 F3 · price: The weighted average sale price for the transaction reported was $28.93, and the range of prices was between $28.51 and $29.44. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| December 19, 2025 Filed Dec 24, 2025 02:40 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | SaleCommon Stock | 57,079 | $28.03 | $1,599,924.37 |
DisclosureSEC source: 0001905871-25-000004 · form4-12242025_021251.xml · nonDerivative · entry 2 Zojwalla Naseem · CIK 0001905871 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 116,918 F2 · price: The weighted average sale price for the transaction reported was $28.03, and the range of prices was between $27.50 and $28.49. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| December 19, 2025 Filed Dec 24, 2025 02:40 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | Exercise / conversionCommon Stock | 40,000 | $15.25 | $610,000.00 |
DisclosureSEC source: 0001905871-25-000004 · form4-12242025_021251.xml · nonDerivative · entry 1 Zojwalla Naseem · CIK 0001905871 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 173,997 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 4,488 shares acquired under the Issuer's Employee Stock Purchase Plan on June 30, 2025. Read SEC document |
| February 28, 2025 Filed Mar 3, 2025 21:19 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | GrantStock Option (Right to Buy) · Derivative | 205,000 | $0.00 Strike: $4.37 | $0.00 |
DisclosureSEC source: 0001415889-25-006158 · form4-03032025_090328.xml · derivative · entry 1 Zojwalla Naseem · CIK 0001905871 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 205,000 Underlying: Common Stock · 205,000 shares Expires 2035-02-27 F1 · derivative.exercise_date: 25% of the shares subject to the option vest on February 28, 2026 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document |
| December 16, 2024 Filed Dec 18, 2024 00:29 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | Exercise / conversionStock Option (Right to Buy) · Derivative | 14,000 | $0.00 Strike: $4.87 | $0.00 |
DisclosureSEC source: 0001415889-24-029683 · form4-12182024_121237.xml · derivative · entry 2 Zojwalla Naseem · CIK 0001905871 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 112,840 Underlying: Common Stock · 14,000 shares Expires 2033-01-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 25% of the shares subject to the option vested on February 1, 2024 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document |
| December 16, 2024 Filed Dec 18, 2024 00:29 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | Exercise / conversionCommon Stock | 14,000 | $4.87 | $68,180.00 |
DisclosureSEC source: 0001415889-24-029683 · form4-12182024_121237.xml · nonDerivative · entry 1 Zojwalla Naseem · CIK 0001905871 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 129,509 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 11, 2024 Filed Dec 12, 2024 00:54 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | SaleCommon Stock | 320 | $9.39 | $3,004.80 |
DisclosureSEC source: 0001415889-24-029026 · form4-12122024_121230.xml · nonDerivative · entry 4 Zojwalla Naseem · CIK 0001905871 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 115,509 F3 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of PRSUs. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. F6 · price: The weighted average sale price for the transaction reported was $9.39, and the range of prices was between $9.31 and $9.74. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| December 11, 2024 Filed Dec 12, 2024 00:54 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | SaleCommon Stock | 14,202 | $8.66 | $122,989.32 |
DisclosureSEC source: 0001415889-24-029026 · form4-12122024_121230.xml · nonDerivative · entry 3 Zojwalla Naseem · CIK 0001905871 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 115,829 F3 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of PRSUs. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. F5 · price: The weighted average sale price for the transaction reported was $8.66, and the range of prices was between $8.22 and $9.21. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| December 10, 2024 Filed Dec 12, 2024 00:54 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | SaleCommon Stock | 13,283 | $9.37 | $124,461.71 |
DisclosureSEC source: 0001415889-24-029026 · form4-12122024_121230.xml · nonDerivative · entry 2 Zojwalla Naseem · CIK 0001905871 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 130,031 F3 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of PRSUs. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. F4 · price: The weighted average sale price for the transaction reported was $9.37, and the range of prices was between $8.89 and $9.67. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| December 09, 2024 Filed Dec 12, 2024 00:54 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | GrantCommon Stock | 52,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-029026 · form4-12122024_121230.xml · nonDerivative · entry 1 Zojwalla Naseem · CIK 0001905871 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 143,314 F1 · shares: On November 11, 2022, the Reporting Person was granted certain performance restricted stock units ("PRSUs") for 80,000 shares, which were subject to vesting upon certification by the Compensation Committee of the Company's achievement of two different performance milestones. 35% of the award previously vested on November 20, 2023. On December 9, 2024, the Compensation Committee certified that the remaining 65% of the award vested based on achievement of certain performance criteria. F2 · balance_after: Includes 1,490 shares acquired under the Issuer's Employee Stock Purchase Plan on June 30, 2024. Read SEC document |
| May 24, 2024 Filed May 28, 2024 21:00 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | Exercise / conversionStock Option (Right to Buy) · Derivative | 9,460 | $0.00 Strike: $4.87 | $0.00 |
DisclosureSEC source: 0001415889-24-014689 · form4-05282024_050502.xml · derivative · entry 2 Zojwalla Naseem · CIK 0001905871 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 126,840 Underlying: Common Stock · 9,460 shares Expires 2033-01-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 25% of the shares subject to the option vested on February 1, 2024 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document |
| May 24, 2024 Filed May 28, 2024 21:00 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | Exercise / conversionCommon Stock | 9,460 | $4.87 | $46,070.20 |
DisclosureSEC source: 0001415889-24-014689 · form4-05282024_050502.xml · nonDerivative · entry 1 Zojwalla Naseem · CIK 0001905871 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 89,824 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 18, 2024 Filed Mar 20, 2024 21:30 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | Exercise / conversionStock Option (Right to Buy) · Derivative | 13,700 | $0.00 Strike: $4.87 | $0.00 |
DisclosureSEC source: 0001415889-24-008762 · form4-03202024_050301.xml · derivative · entry 2 Zojwalla Naseem · CIK 0001905871 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 136,300 Underlying: Common Stock · 13,700 shares Expires 2033-01-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 25% of the shares subject to the option vested on February 1, 2024 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document |
| March 18, 2024 Filed Mar 20, 2024 21:30 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | Exercise / conversionCommon Stock | 13,700 | $4.87 | $66,719.00 |
DisclosureSEC source: 0001415889-24-008762 · form4-03202024_050301.xml · nonDerivative · entry 1 Zojwalla Naseem · CIK 0001905871 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,364 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 01, 2024 Filed Feb 5, 2024 22:30 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | GrantStock Option (Right to Buy) · Derivative | 195,000 | $0.00 Strike: $15.25 | $0.00 |
DisclosureSEC source: 0001415889-24-002609 · form4-02052024_050213.xml · derivative · entry 1 Zojwalla Naseem · CIK 0001905871 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 195,000 Underlying: Common Stock · 195,000 shares Expires 2034-01-31 F1 · derivative.exercise_date: 25% of the shares subject to the option vest on February 1, 2025 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document |
| January 25, 2024 Filed Jan 29, 2024 12:30 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | Exercise / conversionStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $7.02 | $0.00 |
DisclosureSEC source: 0001415889-24-001896 · form4-01292024_070101.xml · derivative · entry 2 Zojwalla Naseem · CIK 0001905871 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 214,000 Underlying: Common Stock · 20,000 shares Expires 2032-01-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 25% of the shares subject to the option vested on January 31, 2023 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document |
| January 25, 2024 Filed Jan 29, 2024 12:30 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | Exercise / conversionCommon Stock | 20,000 | $7.02 | $140,400.00 |
DisclosureSEC source: 0001415889-24-001896 · form4-01292024_070101.xml · nonDerivative · entry 1 Zojwalla Naseem · CIK 0001905871 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,664 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 11, 2023 Filed Dec 12, 2023 22:55 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,900 | $0.00 Strike: $7.02 | $0.00 |
DisclosureSEC source: 0001415889-23-016321 · form4-12122023_051201.xml · derivative · entry 2 Zojwalla Naseem · CIK 0001905871 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 234,000 Underlying: Common Stock · 2,900 shares Expires 2032-01-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 25% of the shares subject to the option vested on January 31, 2023 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document |
| December 11, 2023 Filed Dec 12, 2023 22:55 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | Exercise / conversionCommon Stock | 2,900 | $7.02 | $20,358.00 |
DisclosureSEC source: 0001415889-23-016321 · form4-12122023_051201.xml · nonDerivative · entry 1 Zojwalla Naseem · CIK 0001905871 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,664 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 06, 2023 Filed Dec 8, 2023 01:30 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | Exercise / conversionStock Option (Right to Buy) · Derivative | 13,100 | $0.00 Strike: $7.02 | $0.00 |
DisclosureSEC source: 0001415889-23-015993 · form4-12082023_011253.xml · derivative · entry 2 Zojwalla Naseem · CIK 0001905871 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 236,900 Underlying: Common Stock · 13,100 shares Expires 2032-01-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 25% of the shares subject to the option vested on January 31, 2023 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document |
| December 06, 2023 Filed Dec 8, 2023 01:30 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | Exercise / conversionCommon Stock | 13,100 | $7.02 | $91,962.00 |
DisclosureSEC source: 0001415889-23-015993 · form4-12082023_011253.xml · nonDerivative · entry 1 Zojwalla Naseem · CIK 0001905871 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,764 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 22, 2023 Filed Nov 23, 2023 00:00 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | SaleCommon Stock | 7,095 | $13.89 | $98,549.55 |
DisclosureSEC source: 0001415889-23-015459 · form4-11222023_071111.xml · nonDerivative · entry 4 Zojwalla Naseem · CIK 0001905871 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,664 F3 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of PRSUs. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. F6 · price: The weighted average sale price for the transaction reported was $13.89, and the range of prices was between $13.62 and $14.14. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| November 21, 2023 Filed Nov 23, 2023 00:00 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | SaleCommon Stock | 200 | $15.33 | $3,066.00 |
DisclosureSEC source: 0001415889-23-015459 · form4-11222023_071111.xml · nonDerivative · entry 3 Zojwalla Naseem · CIK 0001905871 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,759 F3 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of PRSUs. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. F5 · price: The weighted average sale price for the transaction reported was $15.33, and the range of prices was between $15.29 and $15.38. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| November 21, 2023 Filed Nov 23, 2023 00:00 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | SaleCommon Stock | 7,261 | $14.83 | $107,680.63 |
DisclosureSEC source: 0001415889-23-015459 · form4-11222023_071111.xml · nonDerivative · entry 2 Zojwalla Naseem · CIK 0001905871 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,959 F3 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of PRSUs. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. F4 · price: The weighted average sale price for the transaction reported was $14.83, and the range of prices was between $14.25 and $15.19. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| November 20, 2023 Filed Nov 23, 2023 00:00 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | GrantCommon Stock | 28,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-015459 · form4-11222023_071111.xml · nonDerivative · entry 1 Zojwalla Naseem · CIK 0001905871 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,220 F1 · shares: On November 11, 2022, the Reporting Person was granted certain performance restricted stock units ("PRSUs") for 80,000 shares, which are subject to vesting upon certification by the Compensation Committee of the Company's achieving two different performance milestones. The Compensation Committee certified on November 20, 2023 that 35% of the award vested based upon the certification by the Compensation Committee as to certain performance criteria. F2 · balance_after: Includes 3,609 shares acquired under the issuer's Employee Stock Purchase Plan on November 15, 2022 and 13,611 shares acquired under the issuer's Employee Stock Purchase Plan on May 15, 2023. Read SEC document |
| February 01, 2023 Filed Feb 2, 2023 22:36 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | GrantStock Option (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $4.87 | $0.00 |
DisclosureSEC source: 0001209191-23-006295 · doc4.xml · derivative · entry 1 Zojwalla Naseem · CIK 0001905871 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2033-01-31 F1 · derivative.exercise_date: 25% of the shares subject to the option vest on February 1, 2024 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document |
| February 01, 2022 Filed Feb 3, 2022 23:59 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | GrantStock Option (Right to Buy) · Derivative | 250,000 | $0.00 Strike: $7.02 | $0.00 |
DisclosureSEC source: 0001415889-22-001054 · form4-02032022_030247.xml · derivative · entry 1 Zojwalla Naseem · CIK 0001905871 · CHIEF MEDICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2032-01-31 F1 · derivative.exercise_date: 25% of the shares subject to the option vest on January 31, 2023 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.